36E79726R0035

PAGE 1 OF

1. REQUISITION NO.

2. CONTRACT NO.

3. AWARD/EFFECTIVE DATE

4. ORDER NO.

5. SOLICITATION NUMBER

6. SOLICITATION ISSUE DATE

a. NAME

b. TELEPHONE NO. (No Collect Calls)

8. OFFER DUE DATE/LOCAL

TIME

9. ISSUED BY

CODE

10. THIS ACQUISITION IS

UNRESTRICTED OR

SET ASIDE:

% FOR:

SMALL BUSINESS

HUBZONE SMALL

BUSINESS

SERVICE-DISABLED

VETERAN-OWNED

SMALL BUSINESS

WOMEN-OWNED SMALL BUSINESS

(WOSB) ELIGIBLE UNDER THE WOMEN-OWNED

SMALL BUSINESS PROGRAM

EDWOSB

8(A)

NAICS:

SIZE STANDARD:

11. DELIVERY FOR FOB DESTINA-

TION UNLESS BLOCK IS

MARKED

SEE SCHEDULE

12. DISCOUNT TERMS

13a. THIS CONTRACT IS A

RATED ORDER UNDER

DPAS (15 CFR 700)

13b. RATING

14. METHOD OF SOLICITATION

RFQ

IFB

RFP

15. DELIVER TO

CODE

16. ADMINISTERED BY

CODE

17a. CONTRACTOR/OFFEROR

CODE

FACILITY CODE

18a. PAYMENT WILL BE MADE BY

CODE

TELEPHONE NO.

UEI:

EFT:

PHONE:

FAX:

17b. CHECK IF REMITTANCE IS DIFFERENT AND PUT SUCH ADDRESS IN OFFER 18b. SUBMIT INVOICES TO ADDRESS SHOWN IN BLOCK 18a UNLESS BLOCK BELOW IS CHECKED

SEE ADDENDUM

19.

20.

21.

22.

23.

24.

ITEM NO.

SCHEDULE OF SUPPLIES/SERVICES

QUANTITY

UNIT

UNIT PRICE

AMOUNT

(Use Reverse and/or Attach Additional Sheets as Necessary)

25. ACCOUNTING AND APPROPRIATION DATA

26. TOTAL AWARD AMOUNT (For Govt. Use Only) 27a. SOLICITATION INCORPORATES BY REFERENCE FAR 52.212-1, 52.212-4. FAR 52.212-3 AND 52.212-5 ARE ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED.

27b. CONTRACT/PURCHASE ORDER INCORPORATES BY REFERENCE FAR 52.212-4. FAR 52.212-5 IS ATTACHED. ADDENDA

ARE

ARE NOT ATTACHED

28. CONTRACTOR IS REQUIRED TO SIGN THIS DOCUMENT AND RETURN _______________

29. AWARD OF CONTRACT: REF. ___________________________________ OFFER

COPIES TO ISSUING OFFICE. CONTRACTOR AGREES TO FURNISH AND

DATED ________________________________. YOUR OFFER ON SOLICITATION

DELIVER ALL ITEMS SET FORTH OR OTHERWISE IDENTIFIED ABOVE AND ON ANY

(BLOCK 5), INCLUDING ANY ADDITIONS OR CHANGES WHICH ARE

ADDITIONAL SHEETS SUBJECT TO THE TERMS AND CONDITIONS SPECIFIED

SET FORTH HEREIN IS ACCEPTED AS TO ITEMS:

30a. SIGNATURE OF OFFEROR/CONTRACTOR 31a. UNITED STATES OF AMERICA (SIGNATURE OF CONTRACTING OFFICER) 30b. NAME AND TITLE OF SIGNER (TYPE OR PRINT) 30c. DATE SIGNED 31b. NAME OF CONTRACTING OFFICER (TYPE OR PRINT) 31c. DATE SIGNED

AUTHORIZED FOR LOCAL REPRODUCTION

(REV. NOV 2021)

PREVIOUS EDITION IS NOT USABLE

Prescribed by GSA - FAR (48 CFR) 53.212

7. FOR SOLICITATION

INFORMATION CALL:

STANDARD FORM 1449

SOLICITATION/CONTRACT/ORDER FOR COMMERCIAL PRODUCTS AND COMMERCIAL SERVICES

OFFEROR TO COMPLETE BLOCKS 12, 17, 23, 24, & 30

36E79726R0035 09-08-2026 Deb Fassl Deborah.Fassl@va.gov 708-786-5894 09-23-2026

2:30 PM CT

Department of Veterans Affairs OPAL / National Acquisition Center Building 37, NCS (003B6C3) 1st Avenue, One Block North of Cermak Hines IL 60141

X

Y 325412 1300 Employees N/A

N/A

See Scope of Contract, Section 2.1 Complete delivery address to be shown on delivery orders.

Department of Veterans Affairs OPAL / National Acquisition Center Building 37, NCS (003B6C3) 1st Avenue, One Block North of Cermak Hines IL 60141

Complete payment address to be shown on orders issued under this contract.

See CONTINUATION Page

2027-2028 Influenza Virus Vaccine

See Schedule of Supplies and Continuation of SF1449

Prices offered shall not exceed two decimal places.

Offered prices must include the Cost Recovery Fee of 0.5%, as outlined in Scope of Contract. Offerors must list an 11 digit NDC number for each offered drug that is unique to the Offeror's company as outlined in scope of contract.

Not Applicable

1 scan

Continuation of SF-1449, Blocks 19 through 24:

All offered pharmaceuticals must be Food and Drug Administration (FDA) approved. FDA’s approval must be verifiable by the Contracting Officer as soon as FDA’s review is complete for the 2027-2028 Influenza season, which may be after the contract award(s).

Please note the following:

· The final vaccine presentation for each line item (Trivalent or Quadrivalent) shall be based on recommendations issued by the World Health Organization (WHO). If WHO recommends both Trivalent and Quadrivalent influenza strain presentations, and both are commercially available from the offeror or contract awardee, the Trivalent presentation shall be required.

· All vaccines shall have an expiration date no earlier than May 31, 2028.

· Syringes may be packaged in boxes of 10; however, each syringe must be individually wrapped and must comply with Scope of Contract, Section 5, Bar Coding, of this solicitation.

· All vaccines shall be latex and preservative free.

FDA recommendations and information can be found at Vaccines Licensed for Use in the United States | FDA.

Offerors are not required to submit an offer for all line items. However, all offered line items for a single presentation must be offered at the same unit price. For example, if submitting an offer including line items 1, 3, 5, and 8 (pre-filled single dose syringes, for persons ≥ 36 months), line items 1, 3, 5, and 8 must be offered at the same unit price.

The presentations are as follows:

2027-2028 INFLUENZA VIRUS VACCINE PRESENTATION

(Pending recommendations from WHO)

Line Item 1

INFLUENZA VIRUS VACCINE

Pre-filled single dose syringes with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free: for persons ≥ 36 months.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to VA Healthcare Facilities and State Veteran Homes (Option 2) as follows:

The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 2

Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free; must be specifically designed for persons 65 years and older as approved by the FDA.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to VA Healthcare Facilities and State Veteran Homes (Option 2) as follows:

The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 3

Pre-filled single dose syringes with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free: for persons ≥ 36 months.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to Bureau of Prisons (BOP) facilities as follows:

The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 4

Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free; must be specifically designed for persons 65 years and older as approved by the FDA.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to BOP facilities as follows:

The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 5

Pre-filled single dose syringes with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free: for persons ≥ 36 months.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to Indian Healthcare Services (IHS) facilities as follows:

The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 6

Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free; must be specifically designed for persons 65 years and older as approved by the FDA.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to IHS facilities as follows:

The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 7

Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season. Must be split virus vaccine (subvirion or purified surface antigen) that has been FDA approved and labeled with indications for administration to children 6 months - 35 months of age (pediatric), latex and preservative free.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to IHS facilities as follows:

The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 8

Pre-filled single dose syringes with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free: for persons ≥ 36 months.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to Captain James A Lovell Federal Health Care Center (FHCC)) as follows:

FHCC will have one delivery that shall be made between August 15, 2027, and September 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Line Item 9

Influenza Virus Vaccine: Pre-filled single dose syringe with plunger and Luer lock needle attachment, Trivalent or Quadrivalent; 2027-2028 influenza season; latex and preservative free; must be specifically designed for persons 65 years and older as approved by the FDA.

Product Name __________________

NDC # __________________

2027 Provisional Federal Ceiling Price $__________________

(Syringe) Box Price (Inclusive of Federal Excise Tax and Cost Recover Fee) Amount (Inclusive of Federal Excise Tax and Cost Recover Fee)

Delivery will be made to Captain James A Lovell Federal Health Care Center (FHCC)) as follows:

FHCC will have one delivery that shall be made between August 15, 2027, and September 15, 2027.

(See SECTION B - CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES, for further delivery instructions.)

Table of Contents

SECTION B - CONTINUATION OF SF 1449 BLOCKS

CONTINUATION OF STANDARD FORM 1449: SCHEDULE OF SUPPLIES/SERVICES

Please be advised, the following paragraphs are also included elsewhere in the solicitation, but are included here for offeror reference.

Proposals will be accepted in Microsoft Word or PDF format via e-mail at Deborah.Fassl@va.gov and Nicholas.McGregor@va.gov with a scanned (pdf) copy of the signed SF-1449. Please note that faxed proposals are not acceptable and will be rejected. Please note, zip files and folders are rejected by the Department of Veterans Affairs (VA) Enterprise Procurement Office (EPO) servers, and emails with large attachments may not be received. VA suggests that offerors submit their proposals well before the deadline and confirm receipt of all attachments with the Contracting Officer listed on the SF-1449.

If the offeror is not the manufacturer of the offered items, the offeror shall submit a Letter of Commitment from the manufacturer to the offeror which will assure the offeror of a source of supply sufficient to satisfy the Government's requirements for the contract period. For the purposes of the Letter of Commitment and current Good Manufacturing Practices (cGMP) acceptability verifications (refer to the solicitation’s Scope of Contract for cGMP details), “Manufacturer” is defined as the entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of active and inactive ingredients to form drug products, whether directly or indirectly by extraction from substances of natural origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis. This process includes the measuring, mixing, weighing, and compounding both the active and inactive ingredients. The product is then converted into various drug forms, suitable for administration through tablets, capsules, liquids (in the form of solutions, suspensions, emulsions, gels, or injectables), creams, ointments, or aerosols. An acceptable Letter of Commitment is required from all distributor-offerors to be eligible for award. The offeror must maintain the same manufacturer and New Drug Application (NDA)/Abbreviated New Drug Application (ANDA)/Biologics License Application (BLA) for the duration of the contract period, unless the Contracting Officer makes a determination that a change in the manufacturer is acceptable. This determination may take place before or after contract award. If the offeror is not a manufacturer, to be eligible for award, offerors must submit a Letter of Commitment that meets all requirements stated in the Addendum to FAR 52.212-1 Instructions to Offerors-Commercial Products and Commercial Services.

Award will be made by solicitation line item. Offerors are not required to submit an offer for every line item; however, the offeror must offer the full quantity for each line item offered. All offered line items for a single presentation must be offered at the same unit price. For example, if submitting an offer including line items 1, 3, 5, and 8 (pre-filled single dose syringes, for persons ≥ 36 months), line items 1, 3, 5, and 8 must be offered at the same unit price.

(Refer to Schedule of Supplies for package size details and estimates)

Offered prices shall include a 0.50% Cost Recovery Fee (See Scope of Contract, Section 11).

The Government will evaluate offers in accordance with the policies and procedures of the FAR Part 12, Part 15, and Part 25.

ITEMS 1 through 7 WILL BE AWARDED UNDER FIRM-FIXED PRICE INDEFINITE DELIVERY, REQUIREMENTS TYPE CONTRACT(S).

(Please refer to FAR clauses 52.216-21 Requirements, 52.216-18 Ordering, 52.216-19 Order Limitations, and 52.247-34 FOB Destination).

1. Contractor(s) shall accept all VA, State Veteran Homes Option 2 (SVH2), Bureau of Prisons (BOP), and Indian Health Service (IHS) orders for line items 1 through 7 from date of contract award through April 15, 2027, unless a later ordering deadline is offered in the contractor’s proposal and is mutually agreed upon between the contractor and the Government. The contractor may, but is not required, to accept orders placed under this contract by VA, SVH2, BOP, and IHS facilities after the specified ordering deadline of April 15, 2027, through the contract expiration date of March 14, 2028. All vaccines shall have an expiration date no earlier than May 31, 2028.

2. Orders will be placed by and delivered to VA, SVH2, BOP, and IHS facilities throughout the United States, the Philippines, and Puerto Rico. Delivery will be required to be made to VA, SVH2, IHS, and BOP in two shipments, unless the ordering facility requests that all items are delivered in a single shipment. The ordering facility must agree, in writing, to receiving entire order in a single shipment. The first shipment of product ordered must be at least 50% of each individual facility’s ordered quantity and must be delivered between August 15, 2027, and September 15, 2027. The second shipment must be for the remaining individual facility’s entire ordered quantity and must be delivered between September 16, 2027, and October 15, 2027. After award of contract, the awardee must abide to the established delivery schedule.

NOTE: Contractor(s) will be required to send confirmation of each order placed by VA, FHCC, SVH2, BOP, and IHS facilities by either email or on-line ordering confirmation within two business days after receipt of order to each individual ordering facility.

ITEMS 8 and 9 WILL BE AWARDED UNDER FIRM-FIXED-PRICE, DEFINITE QUANTITY TYPE CONTRACT(S).

(Please refer to FAR clause 52.247-34 FOB Destination)

1. The delivery orders for these definite quantities will be issued at the time of award by Captain James A. Lovell Federal Healthcare Center (FHCC). The awarded quantities shall be delivered to the FHCC location specified in Section B, Schedule of Supplies/Services in a single delivery between August 15, 2027, and September 15, 2027. All vaccines shall have an expiration date no earlier than May 31, 2028.

2. 100% of the quantities awarded shall be delivered to Captain James A. Lovell Federal Healthcare Center (FHCC), 3001 Green Bay Road, Building 138, North Chicago, IL 60064, between August 15, 2027, and September 15, 2027.

Acknowledgement of Amendments. The following amendments are acknowledged as part of this solicitation. (Please complete if applicable)

The System for Award Management (SAM) is the Official U.S. Government system for registering to do business with the federal government, completing company representations and certifications, listing contract opportunities, and more. Contractors/Offerors should go to http://www.sam.gov to find their information. Training tools are available on the SAM website for familiarization with the SAM system. Prospective contractors shall maintain an uninterrupted, current, and accurate record in the SAM database at the time of proposal submission, during evaluation, and during contract performance. SAM updates are required as necessary, but at least annually.

System updates may lag policy updates. The System for Award Management (SAM) may continue to require entities to complete representations based on provisions that are not included in this solicitation. Contracting officers will rely on representations from offers based on provisions in the solicitation. Entities are not required to, nor are they able to, update their entity registration to remove these representations in SAM.

Subcontracting Plan Requirements: Pursuant to the requirements of 15 U.S.C. § 644, all other than small business concerns are required to have an approved subcontracting plan for contracts valued over $900,000 before the Government can award a contract (see FAR 52.219-9 and VAAR 852.219-70 for details). Offerors must submit a currently approved commercial plan or a new plan for review and approval. Attachment “D” includes all of the elements required to be addressed and is included to facilitate the submission of a subcontracting plan.

As prescribed in FAR Subpart 42.11, VA evaluates contractor performance on all contracts that exceed the Simplified Acquisition Threshold and shares those evaluations with other federal government agencies. The FAR requires that the contractor be provided an opportunity to comment on past performance evaluations prior to each report closing. To fulfill this requirement, VA will be using an online database, the Contractor Performance Assessment Reporting System (CPARS). Annual reporting of past performance will be completed at http://www.cpars.gov.

SCOPE OF CONTRACT

1. INTRODUCTION

1.1 Background. The Influenza Virus Vaccine is procured annually, as pricing and production vary each year based on multiple scientific and epidemiological factors, including global surveillance data, genetic and antigenic characterization, human serology studies, evolutionary trend analysis, integrated data modeling, and vaccine effectiveness evaluations. WHO conducts biannual reviews of the global epidemiological landscape and, when warranted, recommends updated influenza vaccine strain selections for the upcoming season based on the best available evidence.

The VA, BOP, IHS, FHCC, and SVH2 will obtain their annual Influenza Virus Vaccine requirements directly from the contractor(s) awarded under this solicitation. The resulting contract(s) will establish Federal Government pricing for the listed agencies and for all products identified in the Schedule of Supplies. Distribution of these products will be carried out by the awarded contract sources.

1.2 Purpose and Objectives. The purpose of this solicitation is to establish sources of supply that will provide the products listed in the Schedule of Supplies for purchase directly from the awarded contractor(s) (“Contractor”). The objective of such a contract(s) is to ensure availability and distribution of the 2027-2028 Influenza Virus Vaccines to all participants identified, within the specified delivery time frame, and at committed use prices.

1.3 Government Purchase Compliance. Individual VA, SVH2, BOP, and IHS facilities will purchase their requirements by placing orders for the products listed in the schedule directly from the awarded contractor(s) except for Influenza Virus Vaccines provided to VA patients through the VA Community Care Network. In the event that this instance occurs, it will be considered an exception to 52.216-21, Requirements.

FHCC will issue delivery orders for the definite quantities, as listed in the Schedule of Supplies, at the time of award. Products awarded under this contract are for use by the Government agencies listed in the Schedule of Supplies and shall not be subject to resale for commercial purposes.

1.4 Contract Duration. The contract resulting hereunder will be in effect from the contract award date through March 14, 2028. Pre-book periods and delivery timeframes are specified in Section B, Schedule of Supplies/Services, page 10.

2. EXTENT OF OBLIGATION

2.1 Government Participants. The contractor shall provide the products specified in the schedule at the prices awarded herein for the facilities/agencies below:

· All VA facilities

· All Indian Health Service (IHS) facilities

· All Bureau of Prisons (BOP) facilities

· Captain James A. Lovell Federal Health Care Center (FHCC)

· All Option 2 State Veteran Homes (See Section 2.2 State Veteran Homes)

a. All VA facilities, including Consolidated Mail Order Pharmacies, and Emergency Pharmacy Service (Line items 1-2); orders will be placed directly by the individual facilities at time of award through contract ordering deadline.

VA Facilities Authorized to Place Orders for Contract Items 1 through 2 can be accessed at https://www.va.gov/directory/guide/rpt_fac_list.cfm.

b. All BOP facilities (Line items 3-4); orders will be placed directly by the individual facilities at time of award through contract ordering deadline.

BOP Facilities Authorized to Place Orders for Contract Items 3 through 4 can be accessed at BOP: Our Locations.

c. IHS National Supply Service Center in Oklahoma City, OK and Indian Medical Center in Phoenix, AZ (Line items 5-7); orders will be placed directly by the individual facilities at time of award through contract ordering deadline.

d. Option 1 State Veterans Homes are not eligible for national contract prices awarded under this solicitation unless it is specifically named in the Scope of Contract or added after award by mutual agreement.

e. Option 2 State Veterans Homes (SVH2) - The VA Medical Center (VAMC) authorizes the SVH2 to place orders, and the VAMC makes payment for all products ordered by the SVH2. Line items 1-2; orders will be placed by individual SVHs at time of award through contract ordering deadline.

f. FHCC - Delivery to: 3001 Green Bay Road, Building 138, North Chicago, IL 60064. Line items 8- 9; orders will be issued for these definite quantities and provided at the time of award.

2.2 Quantities. The estimated quantities listed in the solicitation for line items 1-7 reflect the estimated usage of VA (including SVH2), BOP, and IHS facilities. There is no expressed or implied guarantee that the estimated quantities will be purchased under this contract(s). Actual quantities purchased may exceed or be less than those represented. Orders that specify the exact quantities and delivery locations will be placed by individual VA, SVH2, BOP, and IHS facilities by the ordering deadline specified in the contract. The Contractor must accept all delivery orders from VA, SVH2, BOP, and IHS facilities that are received by the ordering deadline for quantities that are within the limitations specified in clause 52.216-19, Order Limitations. See also 52.216-18, Ordering and 52.216-21, Requirements.

The quantities listed in the solicitation for items 8-9 reflect the actual quantities that will be ordered by issuance of delivery orders placed against resultant contract(s) at the time of award.

3. Reporting Requirements

3.1 Report of Orders Received (applicable to line items 1 through 9). Starting March 1, 2027, the awarded contractor(s) shall submit an agency‑specific report—provided in Excel format and transmitted via email—detailing all orders received to date for VA, SVH2, BOP, and IHS facilities. An updated version of the report shall be furnished weekly until the established ordering deadline (April 15, 2027, unless a later ordering deadline is offered in the contractor’s proposal and is mutually agreed upon between the contractor and the Government). If any orders are received after the ordering deadline, the contractor(s) shall provide an updated report to reflect those late orders.

At a minimum, each report shall include clearly separated columns or rows identifying:

· Agency

· Facility account number

· Facility name and address

· NDC number

· Quantity ordered by each facility under the resultant contract(s)

For Line Items 1 and 2 (VA), the report shall also include the VA VISN and Facility Station Numbers as required in the Influenza Virus Vaccine Ordering Procedures (see paragraph 3.4). VA facility station numbers are available at: https://www.va.gov/directory/guide/rpt_fac_list.cfm.

Reports shall be submitted to the Contracting Officer at Deborah.Fassl@va.gov, or to another Contracting Officer if subsequently designated by VA.

3.2 Report of Scheduled Deliveries (applicable to all line items). The awarded contractor(s) shall provide to the Contracting Officer an Excel‑formatted report, submitted via email, identifying all scheduled vaccine deliveries to VA, SVH2, BOP, IHS, and FHCC facilities. This report shall be furnished no later than five (5) business days prior to each delivery.

Each report shall clearly identify, at a minimum, by column or row:

· Agency

· Facility account number

· Facility name and address

· NDC number

· Scheduled shipment date(s)

· Approximate quantities For Line Items 1 and 2 (VA), the report shall also include the VA VISN and Facility Station Number as required in the Influenza Virus Vaccine Ordering Procedures (see paragraph 3.4). VA station ID numbers may be accessed at: Facility Listing - Locations (va.gov).

Reports shall be submitted to the Contracting Officer at Deborah.Fassl@va.gov, or to another Contracting Officer if subsequently designated by VA.

Once the contractor provides the Contracting Officer with a shipping schedule, any deviation must be provided via email as soon as the deviation is discovered”, as schedule changes may significantly impact planned VA and Other Government Agency (OGA) influenza clinics.

Delivery windows:

· No deliveries shall be made before 8:00 a.m. or after 2:00 p.m. (local time).

· No deliveries shall occur on weekends or Federal holidays.

3.3 Report of Actual Deliveries (applicable to all line items). The awarded contractor(s) shall submit a weekly Excel‑formatted delivery report to the Contracting Officer via email, detailing all shipments made to VA, SVH2, BOP, IHS, and FHCC facilities. Reporting shall begin upon the initial shipment and continue weekly until all vaccines have been delivered.

Each report shall include, at a minimum, by column or row:

· Agency

· Facility account number

· Facility name

· Shipping address

· NDC number

· Quantity shipped

· Shipment tracking number

For Line Items 1 and 2 (VA), this report shall also include the VA VISN and Facility Station Number in accordance with the Influenza Virus Vaccine Ordering Procedures (see paragraph 3.4).

Reports shall be submitted to the Contracting Officer at Deborah.Fassl@va.gov, or to another Contracting Officer if subsequently designated by VA.

3.4 Ordering Information (applicable to line items 1-7). The awarded contractor(s) shall submit proposed ordering procedures with their proposal, including a sample ordering form, to facilitate order placement by individual facilities. Finalized ordering procedures must be provided via email to Deborah.Fassl@va.gov, or to another Contracting Officer if subsequently designated by VA, within three (3) business days after award.

Orders may be placed via online ordering or email. Ordering information shall include, at a minimum:

· Contract number

· Contract price

· NDC number

· Product description

· Quantity ordered

· Customer shipping and billing information

· Customer information fields, including facility station number (VA station numbers available at Facility Listing - Locations (va.gov)

The contractor(s) shall provide an order confirmation—via email or online system—within two (2) business days of receiving each order.

Reports shall be submitted to the Contracting Officer at Deborah.Fassl@va.gov, or to another Contracting Officer if subsequently designated by VA.

3.5 Delivery Information (applicable to all line items). The awarded contractor(s) shall provide delivery confirmation to the ordering facility for each order placed, by either email or on-line confirmation, no later than three (3) business days prior to scheduled delivery to allow individual facilities appropriate time to coordinate receipt of product.

· Deliveries shall occur no earlier than 8:00 a.m. and no later than 2:00 p.m. (local time).

· No deliveries shall occur on weekends or Federal holidays.

· The Influenza Virus Vaccine must be refrigerated in accordance with FDA guidelines and approval to maintain product efficacy.

· Packaging on deliveries shall clearly indicate “Refrigerated Product.”

4. PACKAGING REQUIREMENTS

Offerors must state the exact name and strength of the drug being supplied as it will appear on the label. Offerors shall also provide a unique 11-digit NDC number for all items offered; the NDC number must be specific to the manufacturing company and to the drug being supplied. The successful offeror/contractor's label shall be the only label on the product. Contractors shall not affix their label over another label on the product. Items are identified in the Schedule of Supplies and in Attachment A. By submitting an offer in response to this solicitation, the offeror certifies that all offered products have passed any required stability testing for all proposed package sizes. Syringes may be packaged in boxes of 10; however, each syringe must be individually wrapped and must comply with Scope of Contract, Section 5, Bar Coding.

5. BAR CODING

All pharmaceutical products provided under this contract shall include bar code labeling at the unit-of-use package level. The bar code labeling must be in a linear format that conforms to all GS1-128 (formerly EAN.UCC) or Health Industry Business Communication Council (HIBCC) Health Industry Bar Code (HIBC) supplier labeling standards. The bar code symbology must comply with all GS1 or HIBCC HIBC parameters including, but not limited to: symbology type or encoded pattern, bar and space dimensions and tolerances, and allowable ratio of wide to narrow elements.

The bar code may be any linear bar code symbology such as GS1-128 (formerly EAN.UCC), GS1 DataBar (formerly RSS), or Universal Product Code (UPC) (if the UPC contains the National Drug Code or NDC). The bar code must encode the NDC, either alone or within the GS1 data structure (Global Trade Item Number (GTIN).

The bar code printing must be American National Standards Institute (ANSI)/International Organization for Standardization (ISO)/IEC Quality Grade C or better. Manufacturers and packagers must ensure that production runs include an initial verification check, as well as routine audits to ensure the bar code is printed clearly and consistently to meet the quality standard of Grade C or better. Contractors shall be responsible for ensuring that bar code labels meet the quality requirements specified in this section prior to shipping pharmaceutical products to any Government Prime Vendor under this contract.

The bar code must be on the outside container or wrapper of the medication as well as on the immediate container, unless the bar code is readily visible and machine-readable through the outside container or wrapper. When the bar code is not easily machine-readable through the over wrap, the over wrap must contain the bar code.

If applicable, the bar code must go on each cell of a blister pack. Furthermore, the bar code must remain intact under normal conditions of use; thus it should not be printed across the perforations of a blister pack.

When applicable to the symbology used, bar codes shall be surrounded by sufficient quiet zone so that the bar code can be scanned correctly. Bar code placement shall minimize curvature of the bar code. For example, bar codes should be placed in “ladder orientation” on vials or bottles to minimize curvature of the bar code. Bar code labeling shall not be placed solely on outer packaging. The Drug Supply Chain Security Act (DSCSA) now requires a two-dimensional data matrix bar code (GS-1 data matrix bar code preferred) for each product down to the lowest saleable package size (see Section 7, below, for additional DSCSA requirements); however, the FDA bar code rule for linear bar codes still applies to all packaging as stated above. A human readable number must be placed adjacent (preferably below) the encoded bar code to ensure product is usable with VA Bar Code Medication Administration (BCMA) in the event the bar code is in some way damaged.

It is recommended that bar code labeling also include the lot number and expiration date. If two separate distinctive bar codes are used, one for NDC and the other for lot number/expiration date; the lot number and expiration date bar code must not be in close proximity to the NDC barcode or in a format that may be confused with the NDC bar code. When applicable, all Healthcare Distribution Alliance (HDA) guidelines (formerly HDMA) shall be followed.

6. DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) REQUIREMENTS

Title II of the Drug Quality and Security Act (DQSA), known as the DSCSA, applies to all drug products, with the exception of those listed on the DSCSA exemption list: Title II of the Drug Quality and Security Act | FDA. As part of the requirement of the DSCSA, drug products are required to provide serialized DSCSA Transaction Information and Transaction Statements using GS1 industry standard Electronic Product Code Information Services (EPCIS) files following the GS1 US Implementation Guideline: The GS1 US DSCSA Implementation Suite (gatewaychecker.com) in order to transmit the files needed for tracking.

DSCSA also requires that all trading partners of manufacturers, wholesale distributors, dispensers, and repackagers meet applicable requirements for being authorized trading partners. The National Association of Boards of Pharmacy (NABP) has established a trading partner directory, which is a repository of authorized trading partners that can be accessed to authenticate authorized trading partners in real time. All VA and other participating agency pharmacies will be entered in this directory as authorized trading partners using unique identifiers. Current and prospective trading partners of the VA other participating agencies are required to complete a registration prior to selling pharmaceuticals to these agencies. Neither the Government, nor the vendors will be charged a fee to participate in the directory.

DSCSA drug products are required to provide the serialized DSCSA Transaction Information and Transaction Statement required for the interoperable electronic DSCSA system using GS1 industry standard EPCIS files following the GS1 US Implementation Guideline. Suppliers establishing an EPCIS connection for DSCSA will need to inform their trading partners of the master data for the Global Trade Item Number (GTIN) and Global Location Numbers (GLNs) that they utilize. These are necessary to establish the EPCIS connection in addition to being able to transmit the file using AS2 or another method. This onboarding must be complete as product may not be purchased or sold without the serial DSCSA Transaction Information. Registration and valid status in the National Association of Boards of Pharmacy (NABP) Trading Partner Directory is required also for all VA contract holders pursuant to DSCSA.

7. NATIONAL DRUG CODES

Offerors shall provide a separate and distinct 11-digit NDC Number unique to the offeror (e.g., 00012-3456-78) for each product proposed, in the space provided following each item listed in the Continuation of SF-1449, Blocks 19 through 24, pages 3-7, of the SF-1449. The first five numbers of the 11-digit NDC number for each product proposed shall identify the offeror. Offers that fail to provide the information required by this paragraph by the solicitation closing date may be rejected and receive no further consideration.

8. DRUG APPLICATION

All offered pharmaceutical products shall be approved by the U.S. Food and Drug Administration (FDA). FDA approval must be verifiable by the Contracting Officer upon completion of FDA’s review for the 2027/2028 influenza season, which may occur after contract award. By signing this solicitation, the offeror certifies that it will have on file—if required by FDA for the products offered—an FDA‑approved New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologic License Application (BLA), as appropriate. Failure to obtain the necessary FDA approval(s) in time to meet the contract’s delivery requirements may result in termination of the contract in accordance with FAR 52.212‑4(m), Termination for Cause. The contractor(s) shall obtain all FDA‑required vaccine batch approvals prior to making any deliveries under the resultant contract.

9. RECALLS

If a drug recall is initiated for any product furnished under this contract—whether the recall is voluntary on the part of the manufacturer or mandated by the FDA—or if the FDA withdraws approval to manufacture any drug covered by this contract, the contractor shall immediately provide written notice of the recall. The contractor shall forward the recall notification, along with all relevant and supporting information, via email to the assigned Contracting Officer and to the following designated recipients:

Karen Ade Chief, Pharmaceutical Division, Acquisition Service 7 VA Enterprise Procurement Office 1st Ave., 1 Block North of Cermak Rd., Bldg. 37 P.O. Box 76, Hines, IL 60141 Karen.Ade@va.gov

Deputy Chief Consultant (M/S119D) VHA Pharmacy Benefits Management Services 1st Ave., 1 Block North of Cermak Rd., Bldg. 37, Rm 139 Hines, IL 60141 Patientlevelrecalls@va.gov

Manager, Product Recall Office National Center for Patient Safety Veterans Health Administration 24 Frank Lloyd Wright Drive, Lobby M Ann Arbor, MI 48106 NCPS@va.gov Phone Number: (734) 930-5890

All Government Prime Vendors that were sent shipments of the affected product(s) shall also be provided a copy of the recall notification along with any pertinent information.

10. COVERED DRUGS

Should a covered drug (as defined in 38 U.S.C. § 8126(h)(2)) be proposed and awarded as a result of this solicitation, the awarded prices shall meet the requirements of 38 U.S.C. § 8126 and shall apply to all Government participants listed in Section 2.1 of the Scope of Contract, regardless of whether the participant is covered under the law. Therefore, prices for the base year and all option years shall not exceed the annually established Federal Ceiling Price (FCP), plus the 0.5% Cost Recovery Fee (CRF).

Attention is directed to the fact that although 38 U.S.C. § 8126 applies to all covered drugs, competitively negotiated and awarded prices for the base year and any option years exercised by the Government will govern unless the annually established FCP results in a price lower than competitively awarded contract prices. In this instance, the contract shall be modified to reflect the lower annually established FCP, plus the 0.5% CRF.

Both parties (Offeror and VA) understand the VA National Contract Service will obtain FCPs from VA’s Pharmacy Benefits Management (PBM). The parties agree the FCP will be calculated pursuant to the requirements of 38 U.S.C. § 8126 and any related requirements contained in the contractor’s Master Agreement, Pharmaceutical Pricing Agreement, and relevant VA Dear Manufacturer Letters. Refer to the VA Federal Supply Schedule (FSS) website at https://www.fss.va.gov/ and Public Law 102-585 (Veterans Health Care Act of 1992) page on the VA FSS website at https://www.va.gov/opal/nac/fss/publicLaw.asp for further information and a list of published Dear Manufacturer Letters.

Contractors submitting a proposal for a covered drug are required to complete the following paragraph:

MASTER AGREEMENTS AND PHARMACEUTICAL PRICING AGREEMENTS

In compliance with 38 U.S.C. § 8126, Offerors of covered drug products (including biologics) must state below whether they currently have a Master Agreement (MA) and a Pharmaceutical Pricing Agreement (PPA), that includes the offered drug products/NDCs, in place with the VA and confirm that the proposed covered drug products are present on the Offeror’s FSS contract or interim agreement.

_____ YES, Offeror has an MA and PPA (inclusive of the proposed drug products/NDCs) in place with VA FSS and proposed drugs are present on Offeror’s FSS contract/interim agreement.

_____ NO, Offeror does not have an MA and PPA (inclusive of the proposed drug products/NDCs) in place with VA FSS and/or products are not present on Offeror’s FSS contract/interim agreement.

Offers of covered drugs (including biologics that fall within 21 CFR § 600.3) will only be considered for award if the Offeror has an executed MA and PPA (which includes the proposed drug products/NDCs) on file with the VA EPO, FSS (in accordance with 38 U.S.C. § 8126(h)(4)(B)). Furthermore, in order to be considered for award under this solicitation, all proposed covered drug products/NDCs must be present on the offeror’s FSS contract or interim agreement with an established Permanent FCP associated with the offeror’s FSS contract or interim agreement by this solicitation’s due date and time for receipt of offers. Offers failing to meet these criteria will be rejected and receive no further consideration.

11. COST RECOVERY FEE AND SUBMISSION OF QUARTERLY SALES REPORTS

11.1 Quarterly Sales Reports. The Contractor shall report all contract sales under this contract and submit collected Cost Recovery Fees as follows:

(A) The Contractor shall accurately report the dollar value, in U.S. dollars and rounded to the nearest whole dollar, of all sales made under this contract by calendar quarter (January 1–March 31, April 1–June 30, July 1–September 30, and October 1–December 31). Reported sales must include all sales made to all authorized contract users. The report shall reflect sales by contract line item and shall segment sales by VA and Other Government Agencies (OGA).